MRGPRB2/X2 and the analogous effects of its agonist and antagonist in DSS-induced colitis in mice
Copyright © 2024. Published by Elsevier Masson SAS..
The mast cell receptor Mrgprb2, a mouse orthologue of human Mrgprx2, is known as an inflammatory receptor and its elevated expression is associated with various diseases such as ulcerative colitis. We aimed to elucidate the role of Mrgprb2/x2 and the effect of its ligands on a chemically induced murine colitis model. We showed that in Mrgprb2-/- mice, there is a differential regulation of cytokine releases in the blood plasma and severe colonic damages after DSS treatment. Unexpectedly, we demonstrated that known Mrgprb2/x2 agonists (peptide P17, P17 analogues and CST-14) and antagonist (GE1111) similarly increased the survival rate of WT mice subjected to 4% DSS-induced colitis, ameliorated the colonic damages of 2.5% DSS-induced colitis, restored major protein mRNA expression involved in colon integrity, reduced CD68+ and F4/80+ immune cell infiltration and restored cytokine levels. Collectively, our findings highlight the eminent role of Mrpgrb2/x2 in conferring a beneficial effect in the colitis model, and this significance is demonstrated by the heightened severity of colitis with altered cytokine releases and inflammatory immune cell infiltration observed in the Mrgprb2 knockout mice. Elevated expression of Mrgprb2 in WT colitis murine models may represent the organism's adaptive protective mechanism since Mrgprb2 knockout results in severe colitis. On the other hand, both agonist and antagonist of Mrgprb2 analogously mitigated the severity of colitis in DSS-induced colitis model by altering Mrgprb2 expression, immune cell infiltration and inflammatory cytokine releases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 174(2024) vom: 27. Apr., Seite 116471 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Duraisamy, Karthi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9042-14-2 |
|---|
| Anmerkungen: |
Date Completed 30.04.2024 Date Revised 30.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2024.116471 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370372905 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370372905 | ||
| 003 | DE-627 | ||
| 005 | 20240430232224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240330s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2024.116471 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1393.xml |
| 035 | |a (DE-627)NLM370372905 | ||
| 035 | |a (NLM)38547764 | ||
| 035 | |a (PII)S0753-3322(24)00355-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Duraisamy, Karthi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MRGPRB2/X2 and the analogous effects of its agonist and antagonist in DSS-induced colitis in mice |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.04.2024 | ||
| 500 | |a Date Revised 30.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Masson SAS. | ||
| 520 | |a The mast cell receptor Mrgprb2, a mouse orthologue of human Mrgprx2, is known as an inflammatory receptor and its elevated expression is associated with various diseases such as ulcerative colitis. We aimed to elucidate the role of Mrgprb2/x2 and the effect of its ligands on a chemically induced murine colitis model. We showed that in Mrgprb2-/- mice, there is a differential regulation of cytokine releases in the blood plasma and severe colonic damages after DSS treatment. Unexpectedly, we demonstrated that known Mrgprb2/x2 agonists (peptide P17, P17 analogues and CST-14) and antagonist (GE1111) similarly increased the survival rate of WT mice subjected to 4% DSS-induced colitis, ameliorated the colonic damages of 2.5% DSS-induced colitis, restored major protein mRNA expression involved in colon integrity, reduced CD68+ and F4/80+ immune cell infiltration and restored cytokine levels. Collectively, our findings highlight the eminent role of Mrpgrb2/x2 in conferring a beneficial effect in the colitis model, and this significance is demonstrated by the heightened severity of colitis with altered cytokine releases and inflammatory immune cell infiltration observed in the Mrgprb2 knockout mice. Elevated expression of Mrgprb2 in WT colitis murine models may represent the organism's adaptive protective mechanism since Mrgprb2 knockout results in severe colitis. On the other hand, both agonist and antagonist of Mrgprb2 analogously mitigated the severity of colitis in DSS-induced colitis model by altering Mrgprb2 expression, immune cell infiltration and inflammatory cytokine releases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biased signalling | |
| 650 | 4 | |a Colitis | |
| 650 | 4 | |a Colonic inflammation | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Immune cell infiltration | |
| 650 | 4 | |a Mrgprx2 | |
| 650 | 7 | |a Dextran Sulfate |2 NLM | |
| 650 | 7 | |a 9042-14-2 |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Receptors, G-Protein-Coupled |2 NLM | |
| 650 | 7 | |a Receptors, Neuropeptide |2 NLM | |
| 700 | 1 | |a Kumar, Mukesh |e verfasserin |4 aut | |
| 700 | 1 | |a Nawabjan, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a Lo, Emily Kwun Kwan |e verfasserin |4 aut | |
| 700 | 1 | |a Hui Lin, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Lefranc, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Bonnafé, Elsa |e verfasserin |4 aut | |
| 700 | 1 | |a Treilhou, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a El-Nezami, Hani |e verfasserin |4 aut | |
| 700 | 1 | |a Leprince, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Chow, Billy K C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 174(2024) vom: 27. Apr., Seite 116471 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:174 |g year:2024 |g day:27 |g month:04 |g pages:116471 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2024.116471 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 174 |j 2024 |b 27 |c 04 |h 116471 | ||